ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer
- PMID: 37980709
- DOI: 10.1245/s10434-023-14585-y
ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer
Abstract
Pancreatic adenocarcinoma is an aggressive disease marked by high rates of both local and distant failure. In the minority of patients with potentially resectable disease, multimodal treatment paradigms have allowed for prolonged survival in an increasingly larger pool of well-selected patients. Therefore, it is critical for surgical oncologists to be abreast of current guideline recommendations for both surgical management and multimodal therapy for pancreas cancer. We discuss these guidelines, as well as the underlying data supporting these positions, to offer surgical oncologists a framework for managing patients with pancreatic adenocarcinoma.
Keywords: Localized pancreatic cancer; Multimodality therapy; Pancreatic cancer guidelines.
© 2023. Society of Surgical Oncology.
References
-
- SEER Cancer Stat Facts: Pancreatic Cancer. National Cancer Institute. Bethesda. https://seer.cancer.gov/statfacts/html/pancreas.html . https://seer.cancer.govhttps://seer.cancer.gov/statfacts/html/pancreas.html . Accessed 30 July 2023.
-
- Society AC. Cancer facts and figures 2021. Atlanta: American Cancer Society; 2021.
-
- Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92–66. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
